Literature DB >> 22446937

The role of nuclear medicine in modern therapy of cancer.

Gabriela Kramer-Marek1, Jacek Capala.   

Abstract

Nuclear medicine is a multidisciplinary field that develops and uses instrumentation and tracers (radiopharmaceuticals) to study physiological processes and noninvasively diagnose, stage, and treat diseases. Particularly, it offers a unique means to study cancer biology in vivo and to optimize cancer therapy for individual patients. A tracer is either a radionuclide alone, such as iodine-131 or a radiolabel in a carrier molecule such as (18)F in fluorodeoxyglucose ((18)F-FDG), or other feasible radionuclide attached to a drug, a protein, or a peptide, which when introduced into the body, would accumulate in the tissue of interest. Nuclear medicine imaging, including single-photon emission computer tomography and positron emission tomography, can provide important quantitative and functional information about normal tissues or disease conditions, in contrast to conventional, anatomical imaging techniques such as ultrasound, computed tomography, or magnetic resonance imaging. For treatment, tumor-targeting agents, conjugated with therapeutic radionuclides, may be used to deposit lethal radiation at tumor sites. This review outlines the role of nuclear medicine in modern cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446937     DOI: 10.1007/s13277-012-0373-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  54 in total

Review 1.  Nuclear medicine applications in molecular imaging.

Authors:  Francis G Blankenberg; H William Strauss
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

Review 2.  Is there still a role for functional radionuclide study of the liver?

Authors:  G Galli; V Valenza
Journal:  Rays       Date:  1997 Apr-Jun

3.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

4.  Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.

Authors:  Paul Chen; Judy Wang; Kristin Hope; Liqing Jin; John Dick; Ross Cameron; Joseph Brandwein; Mark Minden; Raymond M Reilly
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

Review 5.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

6.  Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.

Authors:  Tore Bach-Gansmo; Rimma Danielsson; Ariel Saracco; Brigitte Wilczek; Trond V Bogsrud; Anne Fangberget; Ase Tangerud; Derek Tobin
Journal:  J Nucl Med       Date:  2006-09       Impact factor: 10.057

7.  Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.

Authors:  Morand Piert; Hans-Jürgen Machulla; Maria Picchio; Gerald Reischl; Sybille Ziegler; Piyush Kumar; Hans-Jürgen Wester; Roswitha Beck; Alexander J B McEwan; Leonard I Wiebe; Markus Schwaiger
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

8.  Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma.

Authors:  Li Huo; Zhanhong Wu; Hongming Zhuang; Zhe Fu; Yonghong Dang
Journal:  Clin Nucl Med       Date:  2009-12       Impact factor: 7.794

Review 9.  Targeting of radio-isotopes for cancer therapy.

Authors:  Diane E Milenic; Martin W Brechbiel
Journal:  Cancer Biol Ther       Date:  2004-04-03       Impact factor: 4.742

Review 10.  PET/CT in oncology: for which tumours is it the reference standard?

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more
  12 in total

1.  High expression of M3 muscarinic acetylcholine receptor is a novel biomarker of poor prognostic in patients with non-small cell lung cancer.

Authors:  Jun Wu; Jinxu Zhou; Lei Yao; Yaoguo Lang; Yingnan Liang; Lantao Chen; Jinfeng Zhang; Fengjiao Wang; Yanbo Wang; He Chen; Jianqun Ma
Journal:  Tumour Biol       Date:  2013-07-10

Review 2.  Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.

Authors:  Anna G Sorace; Sara Harvey; Anum Syed; Thomas E Yankeelov
Journal:  Semin Oncol Nurs       Date:  2017-09-15       Impact factor: 2.315

3.  Therapeutic effect of antihypertensive drug on diabetic nephropathy: Functional and structural kidney investigation.

Authors:  Seyedeh Masoumeh Ghoreishi; Mehrangiz Amiri; Ali Shabestani Monfared; Faezeh Hamidi; Hossein Najafzadehvarzi
Journal:  Saudi J Biol Sci       Date:  2022-06-20       Impact factor: 4.052

4.  Gold nanorod-mediated hyperthermia enhances the efficacy of HPMA copolymer-90Y conjugates in treatment of prostate tumors.

Authors:  Brandon Buckway; Nick Frazier; Adam J Gormley; Abhijit Ray; Hamidreza Ghandehari
Journal:  Nucl Med Biol       Date:  2013-12-10       Impact factor: 2.408

5.  Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer.

Authors:  Qiushi Wang; Jingyuan Li; Guanghua Li; Yinghong Li; Chunlin Xu; Ming Li; Guangquan Xu; Songbin Fu
Journal:  Tumour Biol       Date:  2013-08-07

6.  Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.

Authors:  Morten Persson; Masood Hosseini; Jacob Madsen; Thomas J D Jørgensen; Knud J Jensen; Andreas Kjaer; Michael Ploug
Journal:  Theranostics       Date:  2013-08-03       Impact factor: 11.556

7.  Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.

Authors:  Julia Baguña Torres; James C Knight; Michael J Mosley; Veerle Kersemans; Sofia Koustoulidou; Danny Allen; Paul Kinchesh; Sean Smart; Bart Cornelissen
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

Review 8.  Theranostics in nuclear medicine practice.

Authors:  Anna Yordanova; Elisabeth Eppard; Stefan Kürpig; Ralph A Bundschuh; Stefan Schönberger; Maria Gonzalez-Carmona; Georg Feldmann; Hojjat Ahmadzadehfar; Markus Essler
Journal:  Onco Targets Ther       Date:  2017-10-03       Impact factor: 4.147

9.  Evaluation of 99mTc-rhAnnexin V-128 SPECT/CT as a diagnostic tool for early stages of interstitial lung disease associated with systemic sclerosis.

Authors:  Janine Schniering; Li Guo; Matthias Brunner; Roger Schibli; Shuang Ye; Oliver Distler; Martin Béhé; Britta Maurer
Journal:  Arthritis Res Ther       Date:  2018-08-16       Impact factor: 5.156

Review 10.  Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.

Authors:  Amelie Heesch; Jochen Maurer; Elmar Stickeler; Mohsen Beheshti; Felix M Mottaghy; Agnieszka Morgenroth
Journal:  Cells       Date:  2020-10-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.